{"id":1178,"date":"2026-07-04T10:10:00","date_gmt":"2026-07-04T01:10:00","guid":{"rendered":"https:\/\/thesaeron.kr\/?p=1178"},"modified":"2026-07-03T00:20:04","modified_gmt":"2026-07-02T15:20:04","slug":"what-is-bmac-bone-marrow-stem-cell-concentrate","status":"publish","type":"post","link":"https:\/\/thesaeron.kr\/ja\/2026\/07\/04\/what-is-bmac-bone-marrow-stem-cell-concentrate\/","title":{"rendered":"What is BMAC (bone marrow stem cell concentrate)?"},"content":{"rendered":"

I’m Dr. Joo Yong-min of Saeron Clinic, working in regenerative and anti-aging medicine. ‘Does BMAC help autoimmune disease or menopause?’ ‘You harvest marrow and infuse it IV \u2014 is that safe?’ These questions have surged lately. Here I lay out BMAC’s components, mechanisms, and its links to autoimmune disease and menopause \u2014 with evidence, and without hype.<\/p>\n\n

BMAC (bone marrow aspirate concentrate) is an autologous preparation concentrating MSCs, hematopoietic stem cells, growth factors, and IL-1RA from the patient’s own marrow, with safety and efficacy established first in joint treatment. Systemically, immune remodeling, anti-inflammation, and paracrine mechanisms may plausibly affect autoimmune disease and menopause, but large RCTs of systemic BMAC are still lacking, so specialist consultation is needed.<\/p><\/div>\n\n

Key takeaways<\/p>

  1. BMAC is an autologous marrow concentrate carrying MSCs, hematopoietic stem cells, growth factors, and IL-1RA, with accumulating musculoskeletal data.<\/li>
  2. Systemically, four mechanisms \u2014 immune remodeling, reduced chronic inflammation, homing, and paracrine \u2014 are discussed beyond the joint.<\/li>
  3. Autoimmune\/menopause plausibility has mechanistic rationale, but systemic BMAC lacks large RCTs \u2014 don’t equate it with cultured-MSC studies; judge suitability by consultation.<\/li><\/ol><\/div>\n\n
    \n

    What is BMAC (bone marrow stem cell concentrate)?<\/h2>\n

    BMAC (Bone Marrow Aspirate Concentrate) is an autologous biological preparation<\/strong> made by taking a small amount of a patient’s own bone marrow (usually the iliac crest) and centrifuging it to concentrate cells and growth factors. Known first for joint treatment, it’s now drawing interest as an IV procedure for systemic immune modulation.<\/p>\n

    \"An
    BMAC is an autologous preparation from the patient’s own marrow.<\/figcaption><\/figure>\nBMAC’s strength isn’t a single ingredient \u2014 it carries regeneration, immune, and anti-inflammatory signals at once.<\/span>\n

    It’s often compared to PRP, but the composition differs decisively \u2014 mesenchymal stem cells (MSCs) and IL-1RA (which blocks IL-1 inflammatory signaling) are far richer in BMAC.<\/p>\n
    Component<\/th>Main role<\/th>vs PRP<\/th><\/tr><\/thead>
    Mesenchymal stem cell (MSC)<\/td>Tissue regeneration, immune modulation, anti-inflammation<\/td>BMAC only<\/td><\/tr>
    Hematopoietic stem cell (HSC)<\/td>Source of blood and immune cells<\/td>Much higher in BMAC<\/td><\/tr>
    TGF-\u03b2, PDGF, VEGF<\/td>Tissue regeneration, angiogenesis<\/td>Both<\/td><\/tr>
    IL-1RA<\/td>Blocks IL-1 inflammatory signaling<\/td>Higher in BMAC<\/td><\/tr>
    BMP-2, BMP-7<\/td>Bone and cartilage regeneration signals<\/td>BMAC only<\/td><\/tr><\/tbody><\/table>\n\n
    \"Checking
    We verify the cells in BMAC under a microscope.<\/figcaption><\/figure>\n

    From musculoskeletal to systemic \u2014 expanding scope<\/h2>\n

    BMAC already has substantial clinical data in knee and hip osteoarthritis and cartilage\/ligament injury. A systematic review including 876 patients (2024) consistently reported pain reduction, functional gains, and improved quality of life<\/strong>, with some studies showing mid-term durability over PRP and hyaluronic acid.<\/p>\n

    This established local safety and efficacy has become the trust foundation for systemic-use research.<\/p>\n

    876<\/span>patients in a BMAC systematic review (2024)<\/span><\/div>
    Autologous<\/span>no rejection reaction<\/span><\/div>
    IL-1RA<\/span>key systemic anti-inflammatory molecule<\/span><\/div><\/div>\n

    Four mechanisms with systemic infusion<\/h2>\n

    Given intravenously, BMAC is thought to act as follows. 1) Immune remodeling<\/strong> \u2014 MSCs suppress over-activated cytokines like TNF-\u03b1 and IL-1\u03b2 and activate regulatory T cells (Tregs). 2) Reducing chronic low-grade inflammation<\/strong> \u2014 easing the ‘inflammaging’ that rises with age at a systemic level. 3) Stem cell homing<\/strong> \u2014 cells traveling the bloodstream home to inflamed sites and activate repair signals. 4) Paracrine effect<\/strong> \u2014 even without direct differentiation, releasing regenerative signals (exosomes, growth factors) to promote recovery.<\/p>\n\n

    \"Illustration
    Not direct regeneration \u2014 re-tuning the system through ‘signals.’<\/figcaption><\/figure>\n
    Quote-ready \u00b7 citable unit<\/span>Citing figures from cultured-MSC IV studies (like CRATUS) directly as evidence for systemic BMAC is scientifically inaccurate.<\/strong>
    Why<\/span>CRATUS infused hundreds of millions of cultured allogeneic MSCs from another person’s marrow, whereas systemic BMAC uses the patient’s own marrow harvested and centrifuged the same day, infused immediately without culture.<\/span><\/div>
    Example<\/span>CRATUS (Golpanian 2017) reported IV MSC safety in aging-frailty patients, with a significant 6-minute walk increase and reduced TNF-\u03b1.<\/span><\/div>
    Note<\/span>Because cell count, purity, and delivery differ, direct comparison is hard, and no large RCT has yet validated systemic BMAC itself \u2014 treat it as ‘mechanistic rationale.’<\/span><\/div><\/div>\n

    Why autoimmune and menopause draw attention<\/h2>\n

    Autoimmune diseases (like psoriasis) involve immune cells attacking one’s own tissue. Just as biologics block TNF-\u03b1, IL-17, and IL-23, the MSCs and IL-1RA in BMAC engage similar anti-inflammatory pathways.<\/p>\n
    Autoimmune key pathway<\/th>BMAC’s action<\/th><\/tr><\/thead>
    TNF-\u03b1 over-activation<\/td>MSC paracrine effect suppresses TNF-\u03b1 secretion<\/td><\/tr>
    IL-1\u03b2-mediated inflammation<\/td>IL-1RA blocks IL-1 receptor binding<\/td><\/tr>
    T-cell over-response<\/td>MSCs induce regulatory T cells (Tregs)<\/td><\/tr>
    Macrophage M1 polarization<\/td>MSCs promote M2 (anti-inflammatory) differentiation<\/td><\/tr><\/tbody><\/table>\n

    Menopause, too, isn’t just falling estrogen but a mix of ovarian aging, rising systemic inflammation, and declining marrow stem cell activity. In premature ovarian failure (Igboeli 2020), bone-marrow MSCs were reported to raise estrogen by about 150% with menopausal symptoms improving over a year.<\/p>\n

    Direct skin injection \u2014 flushing and rosacea<\/h2>\n

    Beyond systemic use, injecting BMAC directly into the skin is also being tried clinically. Improvement has been reported especially in refractory facial flushing<\/strong> and rosacea<\/strong> that worsen after menopause.<\/p>\n\n

    \"An
    Addressing post-menopausal vascular instability and neurogenic inflammation with regenerative signals.<\/figcaption><\/figure>\n

    The rationale: after menopause, skin vascular instability and neurogenic inflammation increase, and BMAC’s MSCs and growth factors (VEGF, TGF-\u03b2) may act to re-tune vascular signaling and suppress immune over-response. Controlled clinical data is still limited, so mechanistic plausibility and clinical observation are expanding together.<\/p>\n

    In short \u2014 between plausibility and prudence<\/h2>\n

    Regenerative medicine is evolving fast. In areas where clinical practice runs ahead of data \u2014 like systemic BMAC \u2014 deep mechanistic understanding and careful judgment<\/strong> matter most. Being autologous, it carries no rejection and has good short-term safety, but large RCTs are still lacking. Please judge suitability through a specialist consultation.<\/p>\n\n

    \"NAVER
    Saeron Clinic, Yeonsan-dong, Busan \u00b7 by appointment only.<\/figcaption><\/figure>\n<\/div>\n\n

    Checklist<\/p>

    1. Check the state<\/span>